Edesa Biotech, Inc. entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at a price of $4.69 per share for most investors and $5.21 per share for the CEO. The company expects to close the transaction, which involves an aggregate purchase price of approximately $3.5 million, by June 15, 2026, and intends to use the net proceeds to fund the advancement of its vitiligo drug candidate, paridiprubart. Edesa Biotech, Inc. is a biotechnology company focused on developing drug candidates for skin diseases.
